Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity, a study found.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...

Basel: Roche has announced that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed ...

“AlloNK has now demonstrated its ability to significantly enhance the activity of both anti-CD20 rituximab and Affimed’s CD30 ... of standard of care monoclonal antibodies and robust B-cell depletion.

A new study suggests that never-seen-before stem cells in the human retina can restore vision in mice with a common eye disorder. But more work is needed to translate the treatment to people.